Submit Deal

KRONOS (CLINICAL ASSETS)

HQ - Lowell

Summary

Kronos’s clinical assets are drugs in development that inhibit specific enzymes (CDK9 or SYK) to treat cancer or immune-related diseases.

Deals Overview

Total Deals1

Valued Deals0

Total Value-

Avg. Deal Size-

Market Context

Sort

Target: KRONOS (CLINICAL ASSETS)

Bidder: IGNOTA LABS

2 Service Providers

3 Dealmakers

n/a

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy